Novartis CEO Flags Risks From Trump’s MFN Drug Policy As Q1 Earnings Miss Estimates – Novartis (NYSE:NVS)
According to a CNBC report, Narasimhan described it as a “very difficult situation,” and added, “The reality of…
What’s Driving the Market Sentiment Around Novartis AG? – Novartis (NYSE:NVS)
Novartis AG’s (NYSE:NVS) short interest as a percent of float has risen 44.44% since its last report. According…
Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement – Novartis (NYSE:NVS)
Novartis AG (NYSE:NVS) has reportedly reached a confidential settlement with the family of Henrietta Lacks, decades after her…
White House Readies Drug Price Deals With AbbVie, Novartis, Roche – AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN)
AbbVie Inc. (NYSE:ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on…
Itchy Skin Conditions? Novartis’ Pivotal Trial Success Shows Potential For Targeted Relief – Novartis (NYSE:NVS)
Novartis AG (NYSE:AG) on Wednesday released positive topline results from its pivotal Phase 3 RemIND trial of oral…
A Look Into Novartis Inc’s Price Over Earnings – Novartis (NYSE:NVS)
In the current session, the stock is trading at $166.81, after a 1.80% increase. Over the past month,…